Purpose: Diabetic maculopathy can be treated with intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors. However, the therapy is not effective in all patients, and it would be desirable to have parameters for differentiating patients who will benefit from treatment from those who will not. Retinal fixation has been shown to be impaired in patients with low visual acuity (VA) secondary to macular disease, but the changes in fixational eye movements after anti-VEGF treatment for diabetic maculopathy have not been investigated. Methods: Retinal fixation was studied in 29 patients with diabetic macular oedema before three monthly anti-VEGF injections, and 1 and 4 months after the last injection. The change in VA was correlated with changes in area, frequency, amplitude and total number of fixational saccades. Results: During three monthly injections, best-corrected visual acuity (BCVA) increased from (mean AE SD) 74.0 AE 11.5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters to 78.3 AE 9.8 ETDRS letters, (p = 0.003) and central retinal thickness (CRT) decreased from (mean AE SD) 441.7 AE 107.0 lm to 339.5 AE 74.2 lm, (p = <0.0001), which was followed by the opposite changes after treatment (BCVA reduced nonsignificantly to 77.5 AE 10.4 ETDRS letters (p = 0.06), and CRT increased to 393.0 AE 9.8 lm, p = <0.0001). Both improvement and worsening of BCVA correlated with the fixation area (r 2 = 0.28, p = 0.003 and r 2 = 0.14, p = 0.045, respectively), but only improvement of BCVA correlated with the frequency (r 2 = 0.15, p = 0.037) and total number of saccades (r 2 = 0.18, p = 0.02). BCVA showed no correlation with the amplitude and most frequently occurring saccade amplitude. Conclusion: Fixational eye movements may be used to monitor short-term effects of anti-VEGF treatment on diabetic macular oedema. Future studies should aim at investigating a possible predictive value of fixational eye movements for visual function in the long term.
Introduction
Diabetic maculopathy is a frequent cause of visual loss among patients with diabetes mellitus (Yau et al. 2012; Bourne et al. 2013 ). The condition is defined by the presence of retinal oedema and hard exudates in the macular area which becomes clinically significant when it expands and involves the foveal area (ETDRSG 1985) .
Diabetic maculopathy with centre involvement can be treated with intravitreal injection of compounds that reduce leakage of the blood-retina barrier induced by vascular endothelial growth factor (VEGF) (Nguyen et al. 2012; Martin & Maguire 2015) . However, the effect of anti-VEGF therapy is variable and in some patients even absent (Wells et al. 2016) . Therefore, to improve and individualize treatment, it would be desirable to have access to parameters for differentiating patients who will benefit from anti-VEGF therapy from those who will not. This might prevent patients from receiving superfluous injections and might provide the opportunity for a more rapid change to alternative therapies in nonresponders.
Retinal fixation has been shown to be impaired in patients with low visual acuity (VA) secondary to age-related macular degeneration (Møller & Bek 1998; Kumar & Chung 2014) and has been used to monitor the effect of anti-VEGF therapy in this disease (Gonz alez et al. 2011; Pearce et al. 2011; Sivaprada et al. 2011; Pedersen et al. 2016) . Fixational eye movements have also been shown to be disturbed in patients with diabetic retinopathy (Møller & Bek 1998; Kube et al. 2005; Carpineto et al. 2007; Vujosevic et al. 2008 Vujosevic et al. , 2016 , but the value of these movements for monitoring the effect of anti-VEGF treatment in diabetic maculopathy has not been investigated. Therefore, the co-variation between retinal fixation and VA after three monthly anti-VEGF injections in 29 patients with diabetic macular oedema was studied.
Materials and Methods

Design
Prospective observational study of fixational saccades in 29 diabetic patients (21 males and eight females) after anti-VEGF treatment of centre involving diabetic macular oedema.
Patients
Between August 2015 and February 2016, 151 diabetic patients were referred to the Department of Ophthalmology, Aarhus University Hospital, for specialist evaluation of suspected treatment requiring diabetic maculopathy. The patients underwent a routine ophthalmological examination including a measurement of BCVA using Early Treatment Diabetic Retinopathy Study (ETDRS) charts (Ferris et al. 1982 ) and measurement of intraocular pressure (IOP; Tonoref II; Nidek, Gamagori, Aichi, Japan). Mydriasis was induced by tropicamide 1% (MydriacylÒ; Alcon, Copenhagen, Denmark) and phenylephrine 10% (MetaoxedrinÒ; SAD, Skanderborg, Denmark) eye drops, followed by slit lamp examination, 90-D lens biomicroscopy of the retina and fundus photography (TRC-50DX; Topcon, Tokyo, Japan). Optical coherence tomography (OCT) scanning (Heidelberg OCT, version 1.9.10.0; Heidelberg Engineering, Heidelberg, Germany) was performed using the Macular Cube protocol which consisted of 496 horizontal and 512 vertical scans within 6 9 6 mm centred on the fovea. The central retinal thickness (CRT) was calculated as the average retinal thickness inside a ring with a diameter of 6 mm centred on the fovea. All data were entered into a structured patient record that fed a clinical database of all diabetic patients attending the clinic.
Altogether 121 patients were excluded, 28 patients because of previous anti-VEGF treatment, 36 patients previously operated for cataract as the artificial lens induced spurious reflexes hindering the recording of fixational eye movements. Seven patients were diagnosed with another condition than diabetic maculopathy, 26 patients had not treatment requiring maculopathy, and 16 patients had maculopathy not involving the fovea and therefore received retinal photocoagulation, leaving 38 patients with untreated macular oedema as defined in the ETDRS study protocol (Early Treatment Diabetic Retinopathy Study Research Group (ETDRSG) 1985). Among these, nine patients were excluded due to squint (n = 3), practical difficulties in performing the examination (n = 3), lack of cooperation (n = 1), lack of interest in participation after the baseline examination (n = 1) or hospitalization for intercurrent disease (n = 1). The clinical data of the remaining 29 patients who entered the study are shown in Table 1 .
Fixational eye movements
The equipment and the practical procedure are described in details in (Jakobsen et al. 2017 ). The video-based eye tracking system iView X TM High Speed, version 2.7.09 (Senso Motoric Instruments, Berlin, Germany), was used for the examinations. A computer monitor for the generation of visual stimuli was located at a distance of 58 cm in front of the eyes. The patient was positioned in chin and forehead rests and an infrared sensitive video camera mounted to image the reflections of light emitting diodes illuminating the patient's eye from above.
Each examination of fixational eye movements consisted of a calibration procedure where the patient fixated targets with a predefined location, followed by eight sessions (duplicate recordings during monocular and binocular fixation) with the recording of fixational eye movements, each lasting 40 seconds, during fixation of a target in the centre of the computer monitor (Jakobsen et al. 2017) . Data were obtained from the duplicate recordings which were therefore pooled for the analysis. Only data obtained during monocular fixation were used, as binocular fixation has been found to influence the fixation pattern of eyes with reduced VA secondary to diabetic maculopathy (Jakobsen et al. 2017 ).
Follow-up
Fixational eye movements were examined at five successive visits, that is immediately before each of three monthly anti-VEGF injections with aflibercept (2.0 mg), and 1 and 4 months after the third injection. At each of the five visits, measurements of BCVA and CRT were performed similarly to the procedure followed at the baseline examination, except that measurement of CRT at visits two and three was performed using Topcon OCT (Topcon 3D OCT-2000; Topcon Corporation) equipment.
Three patients were excluded from the examination 4 months after the last injection due to nonattendance (n = 1), severe visual loss secondary to vitreous haemorrhage and bilateral optic neuritis (n = 1), or re-treatment of the first treated eye (n = 1), leaving 26 patients for the examination 4 months after the last injection.
Ethical approval
The study was approved by the Regional Committee for Scientific Ethics and was performed in accordance with guidelines of the Declaration of Helsinki. All patients had given their written informed consent for the examinations before enrolment.
Data analysis
Data were analysed from the first treated eye which was the seeing nonamblyopic eye with the lowest VA, and when the VA difference between the two eyes was ≤1 ETDRS letters, the eye with largest CRT was treated, except The stored (x,y) coordinates from the duplicate recordings were scaled on the basis of the amplitude values obtained from the calibration. Subsequently, the data were processed as described by Jakobsen et al. (2017) . In short, a two-step procedure was used to define potential fixation saccades on the basis of a minimum velocity value and a configuration with a fast movement, a directional change and a movement in the new direction (Møller et al. 2002; Bettenb€ uhl et al. 2010) , followed by the extraction of true fixational saccades using a clustering technique (Otero-Millan et al. 2014) . In each patient, the fixation area was described by the bivariate contour ellipse area which represents 68% of the area that includes identified fixation points (Steinman 1965) , the total number of saccades calculated from the area under the curve describing the number of saccades as a function of median saccade amplitude assessed in 0.2 degrees intervals, and the most frequently represented amplitude among these saccades (Jakobsen et al. 2017; .
Statistical analysis
All quantitative measures of fixation, BCVA and CRT were normalized by dividing the value from each visit with the value from the baseline examination. BCVA was not normally distributed and therefore nonparametric statistics were used for all analyses. Friedman's test was used to test for significant differences in BCVA, CRT, fixation area, frequency and amplitude of fixational saccades, the total number and the most frequent amplitude among the four visits. Wilcoxon matched pairs signed rank tests were performed to test for differences between the BCVA, CRT, fixation area, frequency, amplitude, total number and the most frequent occurring amplitude of saccades 1 and 4 months after treatment.
Simple linear regression was used to correlate the change in BCVA with changes in the quantitative measures of fixation and with the change in CRT from before treatment to 4 months after treatment and from 1 to 4 months after treatment.
Results
Before treatment, the overall BCVA in the studied eyes was (mean AE SD) 74.0 AE 11.5 ETDRS letters and the overall CRT was 441.7 AE 107.0 micrometres. Figure 1 shows an example of the fixation pattern (A) before treatment and (B) 1 month after treatment. Figure 2 shows (A) an initial significant increase in BCVA from (mean AE SD) 74.0 AE 11.5 ETDRS letters before treatment to 78.3 AE 9.8 letters 1 month after treatment (p = 0.003), followed by a nonsignificant decrease of 77.5 AE 10.4 letters (p = 0.06). (B) An initial significant reduction in CRT during the same period (p = <0.0001), followed by a significant increase in CRT (p < 0.0001) from 1 to 4 months after treatment. Changes in BCVA showed significant correlations with change in CRT, both during visual improvement (p = 0.0001) and during visual reduction (p = <0.0001). Figure 3 shows that during visual improvement from before treatment to 1 month after treatment, there was a significant negative correlation between the change in BCVA and the change in (A) the fixation area (r 2 = 0.28, p = 0.003), (B) the frequency (r 2 = 0.15, p = 0.037) and (C) the total number of fixational saccades (r 2 = 0.18, p = 0.02), but no correlation between the change in BCVA and amplitude of the saccades (r 2 = 0.001, p = 0.88) or in the most frequently occurring saccade amplitude (r 2 = 0.001, p = 0.85; not shown).
During visual reduction from 1 to 4 months after treatment, there was a significant negative correlation between the change in BCVA and the change in (D) the fixation area (r 2 = 0.14, p = 0.045), but no correlation between BCVA change and (E) the frequency of fixational saccades (r 2 = 0.03, p = 0.38), (F) the total number (r 2 = 0.10, p = 0.10), the amplitude (r 2 = 0.001, p = 0.89) of fixational saccades, or the most frequent amplitude (r 2 = 0.0003, p = 0.93).
Discussion
The present study confirms that three monthly intravitreal injections with anti-VEGF compound can improve VA and reduce thickening of the central retina in diabetic macular oedema (Vujosevic et al. 2016 ). The largest improvement in VA was observed 1 month after treatment which is similar to other findings from patients with diabetic macular oedema treated according to Danish national guidelines (Hodzic-Hadzibegovic et al. 2017) . During the untreated period after the third injection, the functional and anatomical parameters worsened, which increased the focus on followup routines in the clinic to ensure that the patients were offered more frequent injections and other relevant treatment options such as laser photocoagulation (Lang et al. 2017 ) during that period. However, the dual course also provided the opportunity to study the effects of treatment on fixational eye movements during both improvement and worsening of VA and CRT in the same patients. The validity of these measurements was increased by only considering data from monocular fixation which ensured that the masking of unstable fixation by the better eye could be avoided (Jakobsen et al. 2017) . The fact that the decline in BCVA from 1 to 4 months after treatment was not significant may be due to a lack of statistical power.
The finding of a negative correlation between the change in VA and the change in the size of the fixation area estimated by the bivariate contour ellipse area confirms previous studies where visual improvement was accompanied by a reduction in a pathologically increased fixation area in patients with diabetic maculopathy (Møller & Bek 1998; Kube et al. 2005; Carpineto et al. 2007 ). The size of the fixation area is a consequence of the alternating fixation between different retinal loci which is necessary for optimizing VA (Timberlake et al. 1986; Whittaker et al. 1988) . Some of these loci may have been compromised by retinal oedema and necessitated the inclusion of a larger retinal area to encompass a sufficient number of fixation loci (Crossland et al. 2005; Tarita-Nistor et al. 2008; Kumar & Chung 2014) . The observed correlation between a change in VA and the fixation area during both an increase and a decrease in VA indicates that the change in these parameters is coupled in the short-term and suggests that the fixation area might be an indicator of the effects of diabetic macular oedema on retinal function.
The fixation area can be derived from the distribution of amplitudes and directions of fixational saccades, and as the change in VA was found not to correlate with the change in saccade amplitude, it is likely that the change in VA might be related to changes in saccade directions. An enlargement of the amplitude of especially the vertical component of fixational saccades has been reported in patients with low VA secondary to macular disease and increased area of fixation (Møller & Bek 1998) , and the lack of changes in amplitude after therapeutic intervention is supported by similar findings in patients with diabetic maculopathy treated with retinal photocoagulation (Møller & Bek 2000) . The directional characteristics of the fixation pattern after therapeutic interventions might have implications for understanding visual impairment and for designing measures for visual rehabilitation of patients with macular disease. This should be the subject of future investigations.
The fact that a change in VA was negatively correlated with a change in the frequency of fixational saccades can be assumed to be related to fixations remaining for a shorter time in newly included more excentrically located retinal fixation loci with a resulting increase in the total number of saccades. This may potentially be interpreted as a compensatory mechanism to improve contrast sensitivity for low spatial frequencies (Bonneh et al. 2015) . The reduced time for fixation in each fixation locus may together with the lower resolving power in extrafoveal areas contribute to the reduction in VA induced by the disease. However, the correlation between the change in VA and the frequency and total number of fixational saccades was only significant during visual improvement. This may be due to a delayed response, or perhaps irreversibility, of fixation during the recurrence of macular oedema. As worsening of diabetic maculopathy cannot be induced experimentally for ethical reasons, a further investigation of this relation should be performed over a longer period of time on patients not responding to treatment.
The stability of saccade amplitudes during changes in VA was supported by the lack of correlation between changes in VA and the most frequently occurring saccade amplitude. This suggests that the increase in the number of fixational saccades during visual impairment had affected saccades with different amplitudes similarly, and therefore the most frequently occurring saccade might be a basic parameter characterizing neurophysiological aspects of ocular fixation. This might be confirmed by studying the distribution of fixational saccades in diseases of the central nervous system characterized by disturbances in ocular motility.
In conclusion, the present study has identified fixational parameters that covary with both improvement and worsening of VA in the short term. This suggests that the quantification of fixational eye movements may be used to predict shortterm effects of anti-VEGF treatment of diabetic macular oedema on visual function. Future studies with a longer followup time should aim at investigating what duration of retinal oedema is necessary to retain the capacity to reverse VA and the pattern of fixation. This might point to a possible predictive value of fixational eye movements for visual function in the long term.
